Highest-materiality recent filing
Glaukos Q2 net sales $185.6M (+50% YoY); raises FY2026 guidance to $680-700M
Record net sales $185.6M, up 50% YoY; U.S. glaucoma sales $118.5M (+64%).
Glaukos Q1 record sales $150.6M (+41% YoY); raises FY2026 guidance to $620-635M
Record net sales $150.6M (+41% YoY, +39% constant currency).
Glaukos Q4 record sales $143.1M (+36% YoY); reaffirms FY2026 guidance $600-620M
Q4 net sales $143.1M (record), +36% YoY; full year $507.4M, +32% YoY.
Glaukos reports preliminary Q4 2025 net sales ~$143M (+36% YoY); reaffirms FY2026 guidance $600-620M
Q4 2025 net sales ~$143M (+36% YoY); FY2025 net sales ~$507M (+32% YoY).
Glaukos Q3 revenue $133.5M (+38% YoY); raises 2025 guide, introduces 2026 outlook
Record net sales $133.5M, up 38% YoY; U.S. Glaucoma sales $80.8M (+57% YoY).
Glaukos Q2 record net sales $124.1M (+30% YoY); raises FY 2025 guidance to $480-486M
Record net sales $124.1M, up 30% YoY; glaucoma sales $103.5M (+36%), U.S. glaucoma $72.3M (+45%).
Glaukos Q1 net sales record $106.7M (+25% YoY); net loss narrows to $0.32/sh from $0.82
Record Q1 net sales $106.7M, up 25% reported and 26% constant currency vs $85.6M last year.
Glaukos Q4 record net sales $105.5M, +28% YoY; guides FY2025 $475-485M
Q4 net sales record $105.5M, +28% YoY; glaucoma segment $84.1M (+39%).
Glaukos partially unwinds capped calls on 2027 convertible notes; receives cash based on VWAP
Entered into unwind agreements for 50% of capped call transactions associated with $287.5M 2.75% convertible notes due 2027.
Glaukos Q3 revenue $96.7M (+24% YoY), raises 2024 guidance to $377-379M
Record Q3 net sales of $96.7M (+24% YoY); glaucoma segment $76.0M (+30%), corneal health $20.6M (+5%).
Glaukos reports record Q2 sales $95.7M (+19% YoY), raises FY2024 guidance
Record net sales of $95.7M, up 19% reported / 20% constant currency YoY.
Glaukos exchanges $230M of 2.75% convertible notes for 4.25M shares of common stock
Exchanged $230M principal of 2.75% Convertible Senior Notes due 2027 for 4,253,423 common shares and cash.
Glaukos exchanges $230M of 2.75% Convertible Notes due 2027 for common stock
Glaukos entered agreements to repurchase $230M of its 2.75% Convertible Senior Notes due 2027.
Record Q1 net sales of $85.6M (+16% YoY); raised 2024 guidance to $357-$365M
Glaucoma segment sales $67.2M (+20% YoY); Corneal Health $18.4M (+4% YoY).
Glaukos reports record Q4 net sales $82.4M, up 16% YoY; FY2023 sales $314.7M, up 11%
Record Q4 2023 net sales $82.4M, up 16% YoY; glaucoma $60.6M (+15%), corneal health $21.8M (+19%).
Glaukos receives FDA approval for iDose TR; 2024 revenue guidance $350-$360M
FDA approved iDose TR (travoprost intracameral implant) for reducing IOP in OHT or OAG; launch expected late Q1 2024.
Glaukos Q3 net sales up 10% to $78M; raises FY2023 guidance to $307-310M
Net sales $78.0M (+10% YoY); glaucoma $58.3M (+9%), corneal health $19.7M (+12%).
Glaukos Q2 net sales up 11% to $80.4M; raises FY2023 revenue guidance
Q2 net sales $80.4M, +11% YoY; glaucoma sales $61.9M (+10%), corneal health $18.5M (+11% YoY).
Glaukos Q1 net sales rise 9% to $73.9M; guides 2023 sales up; GAAP net loss widens to $34.6M
Q1 2023 net sales $73.9M (+9% YoY); glaucoma $56.2M (+9%), corneal health $17.7M (+10%).
Glaukos Q4 net sales $71.2M, down 3% YoY; full-year net loss $99.2M; guides 2023 sales $290-295M
Q4 net sales $71.2M (-3% YoY); glaucoma $52.9M, corneal health $18.3M.
Glaukos Q3 net loss $27.6M ($0.58 EPS); revenue down 4.6% YoY to $71.3M; raises 2022 sales outlook
Net sales $71.3M, down 4.6% reported (1.6% constant currency) vs $74.7M in Q3 2021.
Glaukos Q2 net sales $72.7M, down 7% YoY; raises FY2022 guidance to $275-280M
Net sales of $72.7M in Q2 2022, down 7% YoY; glaucoma $56.1M, corneal health $16.6M.
Chris M. Calcaterra will step down from his role as the Company’s Chief Operating Officer and will transition to the position of EVP, Global Commercial Operations, effective April 1, 2022.
Joseph E. Gilliam, the Company’s current Chief Financial Officer and Senior Vice President, Corporate Development, has been appointed as the Company’s President and Chief Operating Officer, which appointment will take effect on April 1, 2022.
Alex R. Thurman, the Company’s current Vice President, Finance, has been appointed as the Company’s Senior Vice President, Chief Financial Officer, which appointment will take effect on April 1, 2022.
the independent members of the Board appointed Mark J. Foley, who has served as a member of the Board since 2014 and is the Chair of the Compensation Committee, as the Board’s Lead Independent Director effective December 31, 2021.
the Board, upon the recommendation of the Compensation Committee, appointed Thomas W. Burns, the Company’s President and Chief Executive Officer and a director on the Board since 2002, to serve as the Chairman of the Board of the Company effective upon Dr. Link’s retirement on December 31, 2021.
On December 16, 2021, William J. Link, Ph.D., informed Glaukos Corporation (the “Company”) that he intends to retire from the Company’s Board of Directors (the “Board”) effective December 31, 2021.
Max materiality 0.85 · Median 0.50 · Most common event earnings